Biomerica Inc
NASDAQ:BMRA
Intrinsic Value
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. [ Read More ]
The intrinsic value of one BMRA stock under the Base Case scenario is 0.508 USD. Compared to the current market price of 0.571 USD, Biomerica Inc is Overvalued by 11%.
Valuation Backtest
Biomerica Inc
Run backtest to discover the historical profit from buying and selling BMRA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Biomerica Inc
Current Assets | 8.8m |
Cash & Short-Term Investments | 5.3m |
Receivables | 1.1m |
Other Current Assets | 2.4m |
Non-Current Assets | 1.5m |
Long-Term Investments | 165k |
PP&E | 1m |
Intangibles | 216k |
Other Non-Current Assets | 104k |
Current Liabilities | 2m |
Accounts Payable | 885k |
Accrued Liabilities | 1m |
Other Current Liabilities | 85k |
Non-Current Liabilities | 543k |
Other Non-Current Liabilities | 543k |
Earnings Waterfall
Biomerica Inc
Revenue
|
5.4m
USD
|
Cost of Revenue
|
-4.8m
USD
|
Gross Profit
|
616k
USD
|
Operating Expenses
|
-7.3m
USD
|
Operating Income
|
-6.7m
USD
|
Other Expenses
|
333k
USD
|
Net Income
|
-6.3m
USD
|
Free Cash Flow Analysis
Biomerica Inc
BMRA Profitability Score
Profitability Due Diligence
Biomerica Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
Score
Biomerica Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
BMRA Solvency Score
Solvency Due Diligence
Biomerica Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Biomerica Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BMRA Price Targets Summary
Biomerica Inc
Ownership
BMRA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BMRA Price
Biomerica Inc
Average Annual Return | 16.27% |
Standard Deviation of Annual Returns | 43.7% |
Max Drawdown | -97% |
Market Capitalization | 9.6m USD |
Shares Outstanding | 16 821 600 |
Percentage of Shares Shorted | 0.42% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 49 full-time employees. The firm develops, patents, manufactures and markets diagnostic and therapeutic products for the early detection and monitoring of chronic diseases and other medical conditions. The firm's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the of specific bacteria, hormones, antibodies, antigens, or other substances, in a patient body, stools, or blood, saliva or nasal fluid. The firm is engaged in research and development of disruptive, patented diagnostic guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one BMRA stock under the Base Case scenario is 0.508 USD.
Compared to the current market price of 0.571 USD, Biomerica Inc is Overvalued by 11%.